Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 2/20 | 0.41 |
| ▸ | NPY4R | P50391 | 10/20 | 0.40 |
| ▸ | NPY1R | P25929 | 6/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942412 | 0.96 | NPY4R (0.41) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29493538 | 0.94 | GNPAT (0.40) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29415209 | 0.93 | NOD1 (0.43) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30867028 | 0.92 | NPY4R (0.42) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29750820 | 0.92 | NPY4R (0.42) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31099287 | 0.91 | NOD1 (0.45) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30662552 | 0.91 | NOD1 (0.42) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5849470 | 0.91 | OPRL1 (0.40) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5849482 | 0.91 | OPRL1 (0.40) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31078265 | 0.90 | NPY4R (0.47) | GNPATNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | Merck, Sharp & Dohme LLC (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | GNPAT 1290/4885NPY4R 212/4885NPY1R 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.